AbbVie Inc. compared to other pharma stocks for long-term growth with positive future outlook

From Yahoo Finance: 2025-04-19 11:13:00

AbbVie Inc. (NYSE: ABBV) is compared to other top pharma stocks for long-term growth. A unique trend has seen an increase in Big Pharma acquisitions involving Chinese corporations, reaching 30% in 2024. Chinese pharmaceutical firms are attracting attention due to their development skills and lower-priced medications compared to the US. This trend is expected to continue impacting the US pharmaceutical industry. AbbVie Inc. (ABBV) made $15.1 billion in fiscal Q4 2024, surpassing analyst predictions by 5.6%. The company’s ex-Humira platform led to this growth with sales increasing by over 18% throughout the year. AbbVie Inc. (ABBV) is optimistic about its growth due to popular medications Skyrizi and Rinvoq, expecting sales to exceed $27 billion by 2027. Analysts cite a 5.8% dividend increase in February 2025, continuing the company’s 12-year pattern of dividend growth. Polaris Capital Management noted positive top-line growth from AbbVie’s immunosuppressive drugs in their Q3 2024 investor letter. AbbVie Inc. (ABBV) ranks 4th on the list of best pharma stocks for long-term growth. While pharmaceutical companies show potential, AI stocks are considered to offer higher returns within a shorter timeframe. Check out the report on the cheapest AI stock for more promising opportunities.



Read more at Yahoo Finance: Is AbbVie Inc. (ABBV) the Best Pharma Stock to Buy for Long Term Growth?